CA2797760A1 - Medicament for prophylactic and/or therapeutic treatment of hepatitis c - Google Patents

Medicament for prophylactic and/or therapeutic treatment of hepatitis c Download PDF

Info

Publication number
CA2797760A1
CA2797760A1 CA2797760A CA2797760A CA2797760A1 CA 2797760 A1 CA2797760 A1 CA 2797760A1 CA 2797760 A CA2797760 A CA 2797760A CA 2797760 A CA2797760 A CA 2797760A CA 2797760 A1 CA2797760 A1 CA 2797760A1
Authority
CA
Canada
Prior art keywords
salt
solvate
hmg
coa reductase
reductase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2797760A
Other languages
French (fr)
Inventor
Hisashi Moriguchi
Chifumi Sato
Takatoshi Ozawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Tokyo Medical and Dental University NUC
Original Assignee
Kowa Co Ltd
Tokyo Medical and Dental University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Tokyo Medical and Dental University NUC filed Critical Kowa Co Ltd
Publication of CA2797760A1 publication Critical patent/CA2797760A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A medicinal agent for preventing and/or treating hepatitis C, which comprises a combination of an HMG-CoA reductase inhibitor, a salt thereof or a solvate of the inhibitor or the salt and a non-cyclic retinoid, a salt thereof or a solvate of the retinoid or the salt.

Claims (10)

  1. [Claim 1]
    A medicament for prophylactic and/or therapeutic treatment of hepatitis C, which comprises a combination of an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof, and an acyclic retinoid or a salt thereof, or a solvate thereof.
  2. [Claim 2]
    The medicament according to claim 1, wherein the HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof is pitavastatin or a salt thereof, or a solvate thereof.
  3. [Claim 3]
    The medicament according to claim 1 or 2, wherein the acyclic retinoid is peretinoin.
  4. [Claim 4]
    The medicament according to any one of claims 1 to 3, which is in the form of a single preparation comprising a combination of an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof, and an acyclic retinoid or a salt thereof, or a solvate thereof as an active ingredient.
  5. [Claim 5]
    The medicament according to any one of claims 1 to 3, which comprises a combination of a preparation comprising an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof as an active ingredient, and a preparation containing an acyclic retinoid or a salt thereof, or a solvate thereof as an active ingredient for separate administration of said preparations.
  6. [Claim 6]
    The medicament according to claim 4 or 5, which is in the form of a pharmaceutical composition containing a pharmaceutical additive.
  7. [Claim 7]
    An anti-hepatitis C virus agent, which comprises a combination of an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof, and an acyclic retinoid or a salt thereof, or a solvate thereof.
  8. [Claim 8]
    A medicament for prophylactic and/or therapeutic treatment of hepatic cirrhosis and/or hepatoma caused by HCV infection, which comprises a combination of an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof, and an acyclic retinoid or a salt thereof, or a solvate thereof.
  9. [Claim 9]
    An agent for enhancing action of an anti-hepatitis C virus agent comprising an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof as an active ingredient, which comprises an acyclic retinoid or a salt thereof, or a solvate thereof as an active ingredient.
  10. [Claim 10]
    An agent for enhancing action of an anti-hepatitis C virus agent comprising an acyclic retinoid or a salt thereof, or a solvate thereof as an active ingredient, which comprises an HMG-CoA reductase inhibitor or a salt thereof, or a solvate thereof as an active ingredient.
CA2797760A 2010-04-28 2010-11-08 Medicament for prophylactic and/or therapeutic treatment of hepatitis c Abandoned CA2797760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-102949 2010-04-28
JP2010102949 2010-04-28
PCT/JP2010/069787 WO2011135743A1 (en) 2010-04-28 2010-11-08 Medicinal agent for prevention and/or treatment of hepatitis c

Publications (1)

Publication Number Publication Date
CA2797760A1 true CA2797760A1 (en) 2011-11-03

Family

ID=44861076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2797760A Abandoned CA2797760A1 (en) 2010-04-28 2010-11-08 Medicament for prophylactic and/or therapeutic treatment of hepatitis c

Country Status (4)

Country Link
JP (1) JP2011246432A (en)
AU (1) AU2010352204A1 (en)
CA (1) CA2797760A1 (en)
WO (1) WO2011135743A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103735523B (en) * 2013-12-24 2015-06-17 深圳万乐药业有限公司 Peretinoin medicinal composition
JP6886278B2 (en) * 2016-12-01 2021-06-16 学校法人慶應義塾 Anti-cancer drug

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10167960A (en) * 1996-12-12 1998-06-23 Les-Bell:Kk Hepatocyte cancer recurrence inhibitor
CN100428932C (en) * 2002-05-17 2008-10-29 日研化学株式会社 TGF-alpha expression inhibitors

Also Published As

Publication number Publication date
AU2010352204A1 (en) 2012-11-15
JP2011246432A (en) 2011-12-08
WO2011135743A1 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
HRP20211224T1 (en) Pyrimidine derivatives for the treatment of viral infections
HRP20161379T1 (en) Inhibitors of hepatitis c virus
HRP20161280T1 (en) Pharmaceutical compositions
PH12019502052A1 (en) Hepatitis b virus surface antigen inhibitor
HRP20180237T4 (en) Methods for treating hcv
IL207468A (en) Hcv inhibitors and use thereof for the preparation of medicaments for treatment of hcv infections
HRP20231018T1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
WO2011005646A3 (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
EA201201031A1 (en) HEPATITIS C VIRUS INHIBITORS
HRP20120866T1 (en) Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
IL195025A (en) Cyclopropyl fused indolobenzazepine derivatives and pharmaceutical compositions comprising the same as anti-hcv medicament
EA201100795A1 (en) PHARMACEUTICAL COMPOSITION OF EFFICIENT HSG INHIBITOR FOR ORAL ADMINISTRATION
WO2013123138A3 (en) Spiro [2.4]heptanes for treatment of flaviviridae infections
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
WO2013003629A3 (en) Methods and compositions for inhibition of bone resorption
WO2011156610A3 (en) Quinoline and isoquinoline derivatives as inhibitors of hepatitis c virus
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
RU2012145116A (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC FAT HEPATOSIS AND METHOD FOR PREVENTING OR TREATMENT OF NON-ALCOHOLIC FATTY HEPATOSIS USING IT
HRP20240168T1 (en) Combinations of dolutegravir and lamivudine for the treaetment of hiv infection
HRP20171898T1 (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
IN2014MN01706A (en)
WO2013059278A3 (en) Hepatitis c virus inhibitors
WO2006044968A3 (en) Combination therapy for treating viral infections

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20141110